GlassScriptPhysician profile
William B Hartley
NPI 1831219872
$6,418.88
in general payments reported to CMS, 2019-2025
28 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $364 · 2021: $820 · 2022: $1,256 · 2023: $1,303 · 2024: $785 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,201 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,200.90 |
| Education | $153.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $965.62 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Reveal Linq |
| E.R. Squibb & Sons, L.L.C. | $947.70 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $882.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $586.13 | 2019-2023 | Xarelto |
| Pfizer INC. | $412.69 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.47 | 2019-2025 | Lifevest |
| Abiomed | $323.71 | 2019-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.91 | 2020-2025 | Jardiance |
| Amgen INC. | $308.63 | 2019-2025 | Repatha |
| Philips North America LLC | $281.82 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions |
| Astrazeneca Pharmaceuticals LP | $228.46 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $116.00 | 2023 | Ozempic |
| Merck Sharp & Dohme LLC | $106.43 | 2021-2025 | Verquvo |
| Cvrx, INC. | $84.24 | 2023-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $72.42 | 2023-2024 | Inpefa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $66.15 | 2019-2021 | |
| Astellas Pharma US INC | $55.46 | 2019-2020 | |
| Atricure, INC. | $46.53 | 2020-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Alnylam Pharmaceuticals INC. | $40.26 | 2025 | Amvuttra |
| Amarin Pharma, INC. | $37.63 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $34.16 | 2021-2022 | |
| Bardy Diagnostics, INC. | $30.13 | 2021-2022 | |
| Vital Connect, INC | $29.96 | 2024 | Vitalpatch Rtm |
| Esperion Therapeutics, INC. | $28.25 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $28.21 | 2019 | |
| Edwards Lifesciences Corporation | $26.31 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Baxter Healthcare | $17.01 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hartley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.